Chronic Gout Market Summary
The Chronic Gout market is anticipated to sustain a steady CAGR during the forecast period (2025–2034), driven by rising prevalence linked to aging populations and cardiometabolic comorbidities, improved diagnosis and awareness, an active R&D pipeline spanning xanthine oxidase inhibitors, uricosurics, recombinant uricases, and targeted anti-inflammatories, alongside wider use of advanced diagnostics and growing healthcare expenditure.
Rising cases are attributed to aging and longevity, increasing cardiometabolic risk factors such as obesity, metabolic syndrome, and diabetes, declining kidney function, greater diuretic use, higher purine- and fructose-rich dietary intake, and improved disease detection. Most treatments – including allopurinol, febuxostat, and probenecid – are available as generics, while KRYSTEXXA (pegloticase) remains the sole FDA-approved biologic for refractory cases. Unmet need persists in refractory and tophaceous gout, with emerging therapies like NASP, pozdeutinurad, and lingdolinurad targeting novel mechanisms and improved durability.
- In July 2025, Arthrosi Therapeutics announced over 50% enrollment in its pivotal Phase III REDUCE 1 trial of pozdeutinurad for gout, including tophaceous gout, progressing ahead of schedule with full enrollment expected in H2 2025, running in parallel with REDUCE 2 to evaluate serum urate reduction and tophi resolution.
Explore DelveInsight’s Full Coverage on the Chronic Gout Market – https://www.delveinsight.com/report-store/chronic-gout-market?utm_source=pgnw&utm_medium=pressrelease&utm_campaign=akpr
Chronic Gout Overview
Chronic gout, also known as chronic tophaceous gout, represents the most advanced disease stage, arising when uric acid levels remain inadequately controlled over time. It is characterized by the presence of tophi – visible or palpable urate crystal deposits – in joints, cartilage, bones, bursae, and subcutaneous tissue. These deposits cause joint deformities, limited mobility, and disfigurement, particularly in small joints such as the fingers, and may lead to serious complications including joint destruction and kidney stones. While modern urate-lowering therapies have significantly reduced incidence, patients who progress to this stage often require sustained long-term treatment to manage symptoms, prevent further damage, and potentially resolve existing tophi.
Chronic Gout Diagnosis and Treatment Algorithm
Chronic gout is diagnosed through clinical assessment of sudden, severe joint pain – typically in the first metatarsophalangeal joint – with redness and swelling. Definitive diagnosis relies on identifying monosodium urate crystals in synovial fluid under polarized light microscopy, though this is not always feasible. Elevated serum uric acid supports the diagnosis but does not invariably correlate with symptoms. Imaging modalities such as X-ray, ultrasound, or dual-energy CT can detect urate deposits and exclude alternative diagnoses. Joint aspiration remains the gold standard, particularly in atypical presentations or when infection must be ruled out.
Management targets controlling acute flares and maintaining serum uric acid below 6 mg/dL. Acute attacks are addressed with NSAIDs, colchicine, or corticosteroids. Long-term urate-lowering therapy – typically allopurinol initiated at low dose and titrated to target, with febuxostat as an alternative – forms the backbone of chronic management. Anti-inflammatory prophylaxis with colchicine or NSAIDs for three to six months reduces flare risk upon therapy initiation. Sustained disease control requires ongoing patient education, lifestyle modification, and regular serum urate monitoring.
Chronic Gout Market Players
Key companies operating in the Chronic Gout market research landscape include:
- Amgen
- Sobi/Cartesian Therapeutics
- Arthrosi Therapeutics
- Atom Therapeutics
- And Others.
Chronic Gout Epidemiology
The epidemiology section of the Chronic Gout market insight report provides historical and projected patient population data across the seven major markets (7MM), supported by key opinion leader perspectives that contextualize observed and anticipated trends. Relevant tables and graphs offer a clear view of prevalence patterns, with disclosed assumptions ensuring transparency in data interpretation. This section provides a robust understanding of disease burden across regions.
Key Findings:
- The prevalence of gout among US adults is 3.9%, with a higher burden in men (5.2%) compared to women (2.7%)
- Approximately 13% of patients with gout have chronic gout, marked by uncontrolled serum urate levels and persistent clinical manifestations
- In Germany, gout prevalence among adults is estimated at 1–2%
- In France, gout prevalence in the adult population is approximately 0.9%
- In the UK, gout prevalence is approximately 2.49%
- In Japan, gout prevalence is 1.1%, with a significantly higher rate in men (1.9%) and less than 0.1% in women
- The epidemiology of chronic gout is expected to evolve during the forecast period (2025–2034)
Chronic Gout Market Outlook
The Chronic Gout market trends point to continued expansion through the forecast period (2025–2034), driven by a rising prevalent population, technological advancements, and a growing pipeline of novel therapeutics. Ongoing research and sustained industry commitment hold promise for more effective treatments and potentially transformative therapeutic options for this challenging condition. According to DelveInsight, the chronic gout market across the 7MM is expected to change significantly during the forecast period 2025–2034, reflecting the convergence of unmet clinical need, innovation, and expanding treatment access.
Marketed Chronic Gout Drugs
- KRYSTEXXA (pegloticase) – Amgen
KRYSTEXXA (pegloticase) is a PEGylated uric acid–specific enzyme administered via intravenous injection, indicated for the treatment of chronic gout in adult patients refractory to conventional therapies. By enzymatically converting uric acid to allantoin – a more soluble and readily excreted compound – KRYSTEXXA effectively lowers serum urate levels in patients with uncontrolled gout unresponsive to standard treatment.
- In October 2023, Amgen completed its acquisition of Horizon Therapeutics in a transaction valued at approximately USD 27.8 billion, strengthening its rare disease portfolio
- In July 2022, the US FDA expanded KRYSTEXXA’s labeling to include co-administration with methotrexate for patients with uncontrolled gout
- In September 2010, the US FDA approved KRYSTEXXA for the treatment of gout
Emerging Chronic Gout Drugs
The Chronic Gout market size is expected to evolve gradually, supported by a focused pipeline of emerging therapies addressing significant unmet need. Key emerging candidates include NASP, pozdeutinurad, and lingdolinurad, among others, with active development programs targeting novel mechanisms, improved tolerability, and durable urate control.
- NASP (formerly SEL-212) – Swedish Orphan Biovitrum (Sobi)/Cartesian Therapeutics
NASP (nanoencapsulated sirolimus plus pegadricase) is a novel, once-monthly investigational combination therapy for chronic refractory gout, designed to lower serum urate levels and reduce tissue urate deposits that can lead to gout flares and joint deformities if untreated.
- In July 2024, Sobi began a rolling BLA submission to the US FDA for NASP, backed by pivotal DISSOLVE I and II data, with a regulatory decision anticipated in 2026
- In March 2024, the US FDA granted Fast Track designation to NASP, reflecting the unmet need for new chronic refractory gout therapies
- Since July 2020, Sobi has held rights to develop, register, and commercialize NASP outside China under a licensing deal with Cartesian Therapeutics, with up to approximately USD 585 million in milestone payments and double-digit royalties due to Cartesian based on future net sales
- Pozdeutinurad (AR882) – Arthrosi Therapeutics
Pozdeutinurad (AR882) is a highly potent, selective next-generation URAT1 inhibitor in development for gout, targeting serum urate reduction, flare prevention, and tophi resolution. It is in Phase III for chronic gout management and Phase II for refractory tophaceous gout. In Phase II studies, the 75 mg dose reduced serum urate to below 4 mg/dL in 88% of patients, compared to none with allopurinol or febuxostat, and demonstrated complete tophi resolution in a Phase IIb trial with a favorable safety profile.
- In June 2025, Arthrosi Therapeutics presented two studies at EULAR Congress in Barcelona, highlighting pozdeutinurad’s potential for reducing serum urate, flares, and dissolving tophi in gout and tophaceous gout patients
- In March 2025, Arthrosi Therapeutics completed enrollment ahead of schedule in the pivotal REDUCE 2 trial and dosed the first patient in the replicate REDUCE 1 trial, with both studies running in parallel
- In December 2024, over 50% of patients had been enrolled in the REDUCE 2 trial evaluating pozdeutinurad for serum urate lowering in gout, including tophaceous gout
- In August 2024, the US FDA granted Fast Track Designation to pozdeutinurad for the treatment of clinically visible tophi in patients with gout
- Lingdolinurad (ABP-671) – Atom Therapeutics
ABP-671 is a once-daily oral URAT1 inhibitor that reduces uric acid reabsorption in the kidneys, promoting urinary excretion and lowering serum uric acid levels. Long-term use helps dissolve existing tophi, prevent gout flares, and reduce hyperuricemia-related cardiovascular, renal, and metabolic complications. In a Phase IIa trial, ABP-671 achieved serum urate targets below 6 mg/dL in 93% and below 5 mg/dL in 77% of patients, supporting its advancement to global Phase III trials.
- In May 2025, Atom Therapeutics participated in the Gout Education Society’s Gout Awareness Day; lingdolinurad is currently in Phase IIb/III trials for chronic gout and hyperuricemia
- In November 2024, Atom Therapeutics presented positive Phase I data at ACR Convergence showing ABP-671 was safe, well tolerated, and reduced serum uric acid in all participants with mild to moderate chronic kidney disease
Chronic Gout Drugs Uptake
This section examines the sales uptake of potential chronic gout drugs launched or anticipated to launch between 2020 and 2034, estimating market penetration across countries and evaluating their impact within and across therapeutic classes and segments. It also addresses the financial and regulatory factors contributing to the probability of success of drugs in the chronic gout market.
Emerging therapies are analyzed on the basis of safety and efficacy in randomized clinical trials, order of market entry, broader market dynamics, and the degree to which they address unmet need within the chronic gout treatment landscape.
Download the Chronic Gout market report for in-depth insights on pipeline and forecast
Conclusion
The Chronic Gout market is poised for meaningful growth through 2034, supported by an increasing disease burden, heightened awareness, and continued advancements in therapeutic innovation. While conventional urate-lowering therapies remain the cornerstone of treatment, persistent unmet needs in refractory and tophaceous gout are driving the development of next-generation agents with improved efficacy and durability. Promising pipeline candidates such as NASP, pozdeutinurad, and lingdolinurad have the potential to reshape the treatment landscape and enhance patient outcomes. As research progresses and access to innovative therapies expands, the Chronic Gout market is expected to witness significant transformation, creating new opportunities for stakeholders while addressing the long-term challenges associated with this debilitating condition.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
